by Margy MacMillan
Stepping into the role of ASTCT president over the past two months represents a meaningful culmination of my time serving and growing within our Society. From my first volunteer role in 2011 as...
by Margy MacMillan
This member spotlight features Margaret “Margy” MacMillan, MD, ASTCT president. In this Q&A, she shares insight into her career journey, how ASTCT has supported her growth,...
by Cell Transplantation
Scientists have developed an advanced therapy medicinal product (ATMP) that aims to protect leukemia patients against tumor relapse and potentially fatal infection following haploidentical...
by Translational Oncology
Researchers believe development of chimeric antigen receptor (CAR) T cells targeting the C-X-C chemokine receptor type 4 (CXCR4) could play a role in treating both acute myeloid leukemia (AML) and...
by Transplantation and Cellular Therapy
Clinical study evidence indicates that toxic effects and infections associated with chimeric antigen receptor (CAR) T-cell therapy are leading contributors to non-relapse mortality (NRM) in...
by Transplantation and Cellular Therapy
Researchers report that outpatient (OP) administration of axicabtagene ciloleucel (axi-cel) is a viable alternative to inpatient (IP) delivery of the chimeric antigen receptor (CAR) T-cell therapy...